Live
- Kadapa Municipal Corporation Commissioner Inspects Sanitation and Vehicle Depot Operations
- Piaggio Vehicles commissions its first Motoplex dealership in Visakhapatnam
- RTV's Baseless Allegations Against Kadapa MLA Condemned
- Forever New Announces Triptii Dimri as a Global Brand Ambassador
- Call for Investigation into Illegal Activities of Budda Real Estate
- Indian Railways runs 6556 special Trains during Dasara and Deepawali
- District SP Rohith Raju Hands Over Reward Cheques to Surrendered Maoists
- Zaggle strengthens Leadership with the appointment of ex-Kotak Mahindra Bank’s Virat Diwanji as Additional Director
- Don't read too much into meeting with our Party leaders: DK Suresh
- AG&P Pratham Devoted to Transforming Tada into a Green Town by expanding its CNG infrastructure catering to SRI CITY
Hetero gets nod for generic hepatitis C drug
Highlights
Drug firm Hetero has received nod from the regulator DCGI for its generic Sofosbuvir and Velpatasvir combination tablets used for treatment of chronic hepatitis C.
Hyderabad: Drug firm Hetero has received nod from the regulator DCGI for its generic Sofosbuvir and Velpatasvir combination tablets used for treatment of chronic hepatitis C. The company has received the approval for the generic version of Sofosbuvir+Velpatasvir combination from the Drugs Controller General of India (DCGI),” Hetero said in a statement.
The product will be marketed and distributed under the brand name ‘Velasof’ in India by Hetero Healthcare Ltd, it added. “This fixed-dose combination is the generic version of Gilead’s brand Epclusa, approved by the USFDA for the treatment of patients with chronic hepatitis C genotype 1 to 6,” Hetero said.
Next Story
ADVERTISEMENT
